SlideShare ist ein Scribd-Unternehmen logo
1 von 27
Downloaden Sie, um offline zu lesen
INVESTIGATIONAL NEW DRUG
       APPLICATION
           (IND)



       05-09-2011
INTRODUCTION
What is an IND ?


 An IND is a submission to the food and drug
 administration (FDA) requesting permission to initiate a
 clinical study of a new drug product.


 The Federal Food , Drug and Cosmetic act requires that
  drugs have an approved marketing application before they
  can be shipped in interstate commerce.
 The IND application allows a company to initiate and
  conduct clinical studies for their new drug products.


 The IND application provides the FDA with the data
  necessary to decide whether the new drug and the
  proposed clinical trial pose a reasonable risk to the human
  subjects participating in the study.
When Do I Need An IND ?
 An IND is required any time I want to conduct a clinical
  trial of an unapproved drug.
 An IND would be required to conduct a clinical trail if the
  drug is
 a new chemical entity , not approved for the indication
 under investigation in a new dosage form.
 Being administered at a new dosage level.
 in combination with another drug and the combination is
  not approved.
 All clinical studies where a new drug is administered to
  human subjects , regardless of whether the drug will be
  commercially developed , require an IND.
When You Don’t Need An IND
 An IND is not required to conduct a study if the drug :
 is not intended for human subjects , but is intended for in
  vivo testing or lab research animals (non clinical studies).
 is an approved drug and the study is within its approved
  indication for use.
CATEGORIES OF IND
 COMMERCIAL IND : goal is to obtain marketing approval for a new
  product.
 NON-COMMERCIAL IND : It includes
 INVESTIGATOR IND : In this case ,the physician is both the
  sponsor and investigator.
 EMERGENCY IND : FDA authorize immediate dispensing of a
  non-approved drug in a life threatening situation when no
  standard acceptable therapy is available.
 TREATMENT IND : FDA will permit investigational drug to be
  used to treat a serious or life threaetning disease or if there is
  no comparable alternative drug available.
Pre-IND Meeting
 A meeting between the sponsor and the fda frequently is useful
  in resolving questions and issues raised during the preperation
  of an ind.
 The fda encourages such meetings to the extent that
 They aid in the solution of scientific problems and
 To the extent that the fda has available resources.
 Most issues and questions are usually related to the
 Design of animal studies needed to initiate the clinical trials.
 The scope and design of the initial study in humans.
 Meeting should be scheduled to occur within 60 days of
  the FDA’s receipt of the written request for the meeting.
 A briefing document is required at least 4 weeks prior to
  the meeting.
 The briefing document should provide summary of the
 information related to the product.
ESSENTIALS OF AN IND
 IND must present adequate information to permit the FDA
  to evaluate the drug’s suitability for use in the proposed
  clinical study.
 The central focus of the initial ind should be the general
  investigational plan and the protocol for the 1 st proposed
  human study.
 To assure that the human subjects who participate in the
  proposed study will not be exposed to unreasonable and
  significant risk.
Content And Format Of An IND Application
 The content and format of an initial ind is laid out in 21 CFR
  part 312 .
1. Cover sheet – 312.23(a)(1) FDA form 1571
2. Table of contents – 313.23(a)(2)
3. Introductory statement and general investigational plan –
   312.23(a)(3)
4. Investigators brochure – 312.23(a)(5)
5. Clinical protocol – 312.23(a)(6)
6. Chemistry , manufacturing and control data – 312.23(a)(7)
7. Pharmacological and toxicological information –
312.23(a)(18)
8. Previous human exposure – 312.23(a)(9)
9. Additional information – 312.23(a)(10)
10. Relevant information – 312.23(a)(11)
FORM FDA 1571
1.Name of the sponsor :
 He is the person who takes responsibility for and initiates
  a clinical investigation.
 May be a pharmaceutical company, a private or academic
  organization, or an individual.

2.Date of submission :
 It is the date when the application is mailed to FDA.
3. Address :
 It is the address to which written correspondence from
   FDA should be directed.
4. Telephone number :
 It is the number where the sponsor is usually available
  during normal working hours. A telephone number
  must be provided.
5. Name(s) of Drug :
 List the generic name(s) and trade name, if available.
  Also, state the dosage form(s).
6. IND Number :
 If an emergency IND number was previously assigned by
  FDA, or the Form FDA 1571 is being included with an
  amendment to the original IND, then that IND number
  should be entered here; otherwise, the space should be left
  blank.
7. Indication
8. Phase of clinical investigation to be conducted
9. list no.of all investigational new drug application
10. Serial no.
11. Contents of application
12.Name and title of the person responsible for monitoring
the conduct and progress of clinical investigation
13. Is any part of the clinical study to be conducted by CRO
13. Name and title of the person responsible for review and
evaluation of information relevant to the safety of drug
14. Name of sponsor’s authorised representative
15.Signature
16.Address
17.Telephone no.
18.Date
INTRODUCTORY STATEMENT

 Description of the investigational drug
 All active ingredients
 Drug’s pharmacological classification
 Structural formula
 Route of administration
 Summary of previous human experience
 Formulation of dosage forms
 Objective and planned duration of proposed clinical
  investigation.
INVESTIGATIONAL PLAN
 Description of clinical studies planned for the
  experimental drug
 Purpose of the study
 Indication to be studied
 Types of trials to be initiated
 Number of study subjects
 Risks involved
INVESTIGATORS BROCHURE

 Structural formula of drug.
 Summary of pharmacological , toxicological ,
  pharmacokinetic effects in animals.
 Safety and efficacy
 Purpose of study
 Dose / dose frequency
 Monitoring procedures
CLINICAL PROTOCOL
 a clinical protocol describes how a particular clinical trial
  is to be conducted
 It describes
 the objectives of study
 the trial design
 how subjects are selected
 how the trial is to be carried out
 It should contain the following elements:
 A statement of the objective and purpose of study.
 Name , address and qualification of each investigator
  participating in the study.
 Name and address of each clinical site.
 Study subject inclusion and exclusion criteria.
 Estimate of the number of subjects to be enrolled in the
  study.
Chemistry,Manufacturing and Control Data
 Determines the adequacy of methods used to manufature
  and assay investigational compound
 Safety concerns
 Describe drug substances
 Method of preparation
 Reagent and solvents
 Acceptable limits and analytical methods to ensure quality
  and purity of drug.
Pharmacological and Toxicology data :
 Pharmacology and drug disposition
 Integrated toxicology summary


Previous human exposure :
 Marketed (foreign) or previouly tested in humans.
FDA REVIEW OF THE IND
 Once the ind is stamped as received ,it is sent to the review
  division within CDER.
 On arrival at the review division , it is critically evaluated by
  several reviewers of
 Chemisty
 Biopharmaceutics
 Medical
 Stastistics
 Microbiology
 Pharmacology /toxicology sections
 All these areas review the data submitted with the primary
  purpose to ensure safety of the individual enrolled in th e
  study.
 Once an IND is submitted,the study can’t be initiated until
  a period of 30 days.
 If there are any major issues relating to the safety of the
  volunteers in the proposed study , the FDA can institute a
  clinical hold.
IND ANNUAL REPORTS
 Sponsors should submit an annual report that provides the
  FDA with a brief update on the progress of all
  investigations included in the IND.
 It should contain the following:
 Individual study information.
 Summary of the study.
 Listing of any significant foreign marketing developments
  with the drug e.g. approval in another country.
AAKRATI GUPTA
 2011H108048H

Weitere ähnliche Inhalte

Was ist angesagt?

Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application Kirsha K S
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochureksreekar888
 
Schedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaSchedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaAkshdeep Sharma
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsNimmiRoy
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Dr B Naga Raju
 
New drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdfNew drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdfcrazyboy92
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by ValentynaValentyna Korniyenko
 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)Turacoz Skill Development Program
 
Features of clinical trials
Features of clinical trialsFeatures of clinical trials
Features of clinical trialsDRASHTI PATEL
 
NDA- New Drug Application
NDA- New Drug ApplicationNDA- New Drug Application
NDA- New Drug ApplicationDr. Jigar Vyas
 
Clinical Trial Protocol.pptx
Clinical Trial Protocol.pptxClinical Trial Protocol.pptx
Clinical Trial Protocol.pptxVenugopal N
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]Sagar Savale
 
SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019Shweta Lal
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Manish Rajput
 
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]Vikas Dhiman
 

Was ist angesagt? (20)

Investigational new drug
Investigational new drugInvestigational new drug
Investigational new drug
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochure
 
NDA IND and ANDA
NDA IND and ANDANDA IND and ANDA
NDA IND and ANDA
 
Schedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaSchedule Y by akshdeep sharma
Schedule Y by akshdeep sharma
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologics
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
 
New drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdfNew drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdf
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by Valentyna
 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 
Features of clinical trials
Features of clinical trialsFeatures of clinical trials
Features of clinical trials
 
New ct rule 2019
New ct rule 2019New ct rule 2019
New ct rule 2019
 
NDA- New Drug Application
NDA- New Drug ApplicationNDA- New Drug Application
NDA- New Drug Application
 
Clinical Trial Protocol.pptx
Clinical Trial Protocol.pptxClinical Trial Protocol.pptx
Clinical Trial Protocol.pptx
 
INFORMED CONSENT FORM
INFORMED CONSENT FORMINFORMED CONSENT FORM
INFORMED CONSENT FORM
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]
 
BA and BE studies
BA and BE studiesBA and BE studies
BA and BE studies
 
SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
 

Andere mochten auch

New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)Vamsikrishna Reddy
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Sagar Savale
 
Abriviated new drug application
Abriviated new drug applicationAbriviated new drug application
Abriviated new drug applicationGaurav Kr
 
The Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) ProcessThe Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) ProcessCarrie O'Connor
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoAnthony Melvin Crasto Ph.D
 
Steps involved in dosage development of new drug
Steps involved in dosage development of new drugSteps involved in dosage development of new drug
Steps involved in dosage development of new drugmadhuri muramshetty
 
Drugs approved in 2010
Drugs approved in 2010Drugs approved in 2010
Drugs approved in 2010Naveen Kumar
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and ndaswati2084
 
New Drug Application [NDA]
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]Sagar Savale
 
Pharmaceutical waste management
Pharmaceutical waste managementPharmaceutical waste management
Pharmaceutical waste managementImad Nmeir
 
PHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIAPHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIAAakashdeep Raval
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentKarun Kumar
 
Pharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal PracticesPharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal Practicesrekhac86
 

Andere mochten auch (18)

New drug application
New drug applicationNew drug application
New drug application
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]
 
Abriviated new drug application
Abriviated new drug applicationAbriviated new drug application
Abriviated new drug application
 
The Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) ProcessThe Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) Process
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
 
Nda ipr
Nda  iprNda  ipr
Nda ipr
 
Steps involved in dosage development of new drug
Steps involved in dosage development of new drugSteps involved in dosage development of new drug
Steps involved in dosage development of new drug
 
Drugs approved in 2010
Drugs approved in 2010Drugs approved in 2010
Drugs approved in 2010
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
 
Drug Discovery New Drug Development Process
Drug Discovery New Drug Development ProcessDrug Discovery New Drug Development Process
Drug Discovery New Drug Development Process
 
New Drug Development Process
New Drug Development ProcessNew Drug Development Process
New Drug Development Process
 
New Drug Application [NDA]
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]
 
Pharmaceutical waste management
Pharmaceutical waste managementPharmaceutical waste management
Pharmaceutical waste management
 
ANDA filing
ANDA filingANDA filing
ANDA filing
 
PHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIAPHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIA
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Pharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal PracticesPharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal Practices
 

Ähnlich wie Investigational new drug application new

IND(Investigational New Drug Application).pptx
IND(Investigational New Drug Application).pptxIND(Investigational New Drug Application).pptx
IND(Investigational New Drug Application).pptxSrinuKN
 
Investigational New Drug Application enabling studies.pptx
Investigational New Drug Application enabling studies.pptxInvestigational New Drug Application enabling studies.pptx
Investigational New Drug Application enabling studies.pptxNikitaBankoti2
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...Audumbar Mali
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Saiyad Arsh zia
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
 
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxDilsarGohil1
 
Investigational new drug application (ind)
Investigational new drug application (ind)Investigational new drug application (ind)
Investigational new drug application (ind)Siddu K M
 
GLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptxGLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptxRAHUL PAL
 
GLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptxGLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptxPrachi Pandey
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationDr. Jigar Vyas
 
investigational new drug application
investigational new drug applicationinvestigational new drug application
investigational new drug applicationshiv
 
IND Enabling Studies (IND)
IND Enabling Studies  (IND)IND Enabling Studies  (IND)
IND Enabling Studies (IND)Anurag Chourasia
 
Investigational New Drug application
Investigational New Drug applicationInvestigational New Drug application
Investigational New Drug applicationomkarjanjire2
 
INVESTIGATIONAL NEW DRUG APPLICATION.pptx
INVESTIGATIONAL NEW DRUG APPLICATION.pptxINVESTIGATIONAL NEW DRUG APPLICATION.pptx
INVESTIGATIONAL NEW DRUG APPLICATION.pptxMohammed Sadhiq M S
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavKashikant Yadav
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONKomal Yadav
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug ApplicationSuhas Reddy C
 

Ähnlich wie Investigational new drug application new (20)

Ind 30
Ind 30Ind 30
Ind 30
 
IND(Investigational New Drug Application).pptx
IND(Investigational New Drug Application).pptxIND(Investigational New Drug Application).pptx
IND(Investigational New Drug Application).pptx
 
Investigational New Drug Application enabling studies.pptx
Investigational New Drug Application enabling studies.pptxInvestigational New Drug Application enabling studies.pptx
Investigational New Drug Application enabling studies.pptx
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
Indstudies
Indstudies Indstudies
Indstudies
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
 
Investigational new drug application (ind)
Investigational new drug application (ind)Investigational new drug application (ind)
Investigational new drug application (ind)
 
GLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptxGLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptx
 
GLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptxGLOBAL SUBMISSION ON IND.pptx
GLOBAL SUBMISSION ON IND.pptx
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug Application
 
investigational new drug application
investigational new drug applicationinvestigational new drug application
investigational new drug application
 
IND Enabling Studies (IND)
IND Enabling Studies  (IND)IND Enabling Studies  (IND)
IND Enabling Studies (IND)
 
Investigational New Drug application
Investigational New Drug applicationInvestigational New Drug application
Investigational New Drug application
 
INVESTIGATIONAL NEW DRUG APPLICATION.pptx
INVESTIGATIONAL NEW DRUG APPLICATION.pptxINVESTIGATIONAL NEW DRUG APPLICATION.pptx
INVESTIGATIONAL NEW DRUG APPLICATION.pptx
 
6 ind
6 ind6 ind
6 ind
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant Yadav
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 

Investigational new drug application new

  • 1. INVESTIGATIONAL NEW DRUG APPLICATION (IND) 05-09-2011
  • 2. INTRODUCTION What is an IND ?  An IND is a submission to the food and drug administration (FDA) requesting permission to initiate a clinical study of a new drug product.  The Federal Food , Drug and Cosmetic act requires that drugs have an approved marketing application before they can be shipped in interstate commerce.
  • 3.  The IND application allows a company to initiate and conduct clinical studies for their new drug products.  The IND application provides the FDA with the data necessary to decide whether the new drug and the proposed clinical trial pose a reasonable risk to the human subjects participating in the study.
  • 4. When Do I Need An IND ?  An IND is required any time I want to conduct a clinical trial of an unapproved drug.  An IND would be required to conduct a clinical trail if the drug is  a new chemical entity , not approved for the indication under investigation in a new dosage form.  Being administered at a new dosage level.  in combination with another drug and the combination is not approved.
  • 5.  All clinical studies where a new drug is administered to human subjects , regardless of whether the drug will be commercially developed , require an IND.
  • 6. When You Don’t Need An IND  An IND is not required to conduct a study if the drug :  is not intended for human subjects , but is intended for in vivo testing or lab research animals (non clinical studies).  is an approved drug and the study is within its approved indication for use.
  • 7. CATEGORIES OF IND  COMMERCIAL IND : goal is to obtain marketing approval for a new product.  NON-COMMERCIAL IND : It includes  INVESTIGATOR IND : In this case ,the physician is both the sponsor and investigator.  EMERGENCY IND : FDA authorize immediate dispensing of a non-approved drug in a life threatening situation when no standard acceptable therapy is available.  TREATMENT IND : FDA will permit investigational drug to be used to treat a serious or life threaetning disease or if there is no comparable alternative drug available.
  • 8. Pre-IND Meeting  A meeting between the sponsor and the fda frequently is useful in resolving questions and issues raised during the preperation of an ind.  The fda encourages such meetings to the extent that  They aid in the solution of scientific problems and  To the extent that the fda has available resources.  Most issues and questions are usually related to the  Design of animal studies needed to initiate the clinical trials.  The scope and design of the initial study in humans.
  • 9.  Meeting should be scheduled to occur within 60 days of the FDA’s receipt of the written request for the meeting.  A briefing document is required at least 4 weeks prior to the meeting.  The briefing document should provide summary of the information related to the product.
  • 10. ESSENTIALS OF AN IND  IND must present adequate information to permit the FDA to evaluate the drug’s suitability for use in the proposed clinical study.  The central focus of the initial ind should be the general investigational plan and the protocol for the 1 st proposed human study.  To assure that the human subjects who participate in the proposed study will not be exposed to unreasonable and significant risk.
  • 11. Content And Format Of An IND Application  The content and format of an initial ind is laid out in 21 CFR part 312 . 1. Cover sheet – 312.23(a)(1) FDA form 1571 2. Table of contents – 313.23(a)(2) 3. Introductory statement and general investigational plan – 312.23(a)(3) 4. Investigators brochure – 312.23(a)(5) 5. Clinical protocol – 312.23(a)(6) 6. Chemistry , manufacturing and control data – 312.23(a)(7)
  • 12. 7. Pharmacological and toxicological information – 312.23(a)(18) 8. Previous human exposure – 312.23(a)(9) 9. Additional information – 312.23(a)(10) 10. Relevant information – 312.23(a)(11)
  • 13. FORM FDA 1571 1.Name of the sponsor :  He is the person who takes responsibility for and initiates a clinical investigation.  May be a pharmaceutical company, a private or academic organization, or an individual. 2.Date of submission :  It is the date when the application is mailed to FDA. 3. Address :  It is the address to which written correspondence from FDA should be directed.
  • 14. 4. Telephone number :  It is the number where the sponsor is usually available during normal working hours. A telephone number must be provided. 5. Name(s) of Drug :  List the generic name(s) and trade name, if available. Also, state the dosage form(s).
  • 15. 6. IND Number :  If an emergency IND number was previously assigned by FDA, or the Form FDA 1571 is being included with an amendment to the original IND, then that IND number should be entered here; otherwise, the space should be left blank. 7. Indication 8. Phase of clinical investigation to be conducted 9. list no.of all investigational new drug application
  • 16. 10. Serial no. 11. Contents of application 12.Name and title of the person responsible for monitoring the conduct and progress of clinical investigation 13. Is any part of the clinical study to be conducted by CRO 13. Name and title of the person responsible for review and evaluation of information relevant to the safety of drug 14. Name of sponsor’s authorised representative 15.Signature 16.Address 17.Telephone no. 18.Date
  • 17. INTRODUCTORY STATEMENT  Description of the investigational drug  All active ingredients  Drug’s pharmacological classification  Structural formula  Route of administration  Summary of previous human experience  Formulation of dosage forms  Objective and planned duration of proposed clinical investigation.
  • 18. INVESTIGATIONAL PLAN  Description of clinical studies planned for the experimental drug  Purpose of the study  Indication to be studied  Types of trials to be initiated  Number of study subjects  Risks involved
  • 19. INVESTIGATORS BROCHURE  Structural formula of drug.  Summary of pharmacological , toxicological , pharmacokinetic effects in animals.  Safety and efficacy  Purpose of study  Dose / dose frequency  Monitoring procedures
  • 20. CLINICAL PROTOCOL  a clinical protocol describes how a particular clinical trial is to be conducted  It describes  the objectives of study  the trial design  how subjects are selected  how the trial is to be carried out
  • 21.  It should contain the following elements:  A statement of the objective and purpose of study.  Name , address and qualification of each investigator participating in the study.  Name and address of each clinical site.  Study subject inclusion and exclusion criteria.  Estimate of the number of subjects to be enrolled in the study.
  • 22. Chemistry,Manufacturing and Control Data  Determines the adequacy of methods used to manufature and assay investigational compound  Safety concerns  Describe drug substances  Method of preparation  Reagent and solvents  Acceptable limits and analytical methods to ensure quality and purity of drug.
  • 23. Pharmacological and Toxicology data :  Pharmacology and drug disposition  Integrated toxicology summary Previous human exposure :  Marketed (foreign) or previouly tested in humans.
  • 24. FDA REVIEW OF THE IND  Once the ind is stamped as received ,it is sent to the review division within CDER.  On arrival at the review division , it is critically evaluated by several reviewers of  Chemisty  Biopharmaceutics  Medical  Stastistics  Microbiology  Pharmacology /toxicology sections
  • 25.  All these areas review the data submitted with the primary purpose to ensure safety of the individual enrolled in th e study.  Once an IND is submitted,the study can’t be initiated until a period of 30 days.  If there are any major issues relating to the safety of the volunteers in the proposed study , the FDA can institute a clinical hold.
  • 26. IND ANNUAL REPORTS  Sponsors should submit an annual report that provides the FDA with a brief update on the progress of all investigations included in the IND.  It should contain the following:  Individual study information.  Summary of the study.  Listing of any significant foreign marketing developments with the drug e.g. approval in another country.